Life Technologies won Chinese approval for one of its gene analyzers, and the company is launching 10 assays to grow its share of the country's fast-growing market, all while a who's-who of competitors and private equity firms mull bids for the sequencing giant.
The maker of coronary and peripheral artery disease treatment devices inked a deal with Weihai Weigao Medical Devices to distribute its products to hospitals and other health care venues throughout the country.
A South African shipping company is making a run at taking control of Adcock Ingram, the country's second largest drugmaker, and given its board until next week to decide if it is onboard with the deal.
DKSH, a pharma market-services contractor, has re-upped with Bayer Healthcare to help the drug giant expand its presence in Cambodia, agreeing to handle importation, regulatory clearance and distribution in the Asian nation.
Chinese CRO ShangPharma won shareholder approval for its effort to get off the New York Stock Exchange and go private, a plan that involves selling the company to private equity firms and some of the CRO's leadership.
Last year Sanofi boss Chris Viehbacher ran out his list of his favorite emerging market opportunities including Colombia, Indonesia and Vietnam. A new rundown on recent developments in Vietnam, show the many reasons why Viehbacher would see the southeast Asian country as a very good bet.
The logistics of getting drugs delivered in underdeveloped countries can be tricky. Many companies turn to partners with the expertise that can help them navigate the import laws and distribution obstacles that those countries present.
Diabetes is rampant in China, and growing. And relatively few of the more than 90 million Chinese diabetics are treated. It's no wonder that pharma companies are piling into China, diabetes treatments in tow.
India's government is taking seriously the call to better regulate clinical trials, and now the country is planning to launch two independent committees tasked with overseeing the process.
Mitsubishi has been building up its pharmaceutical business and is expanding it further with a new deal to partner up with an API producer in India.